Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
688208 Autel Intelligent Technology Corp.,Ltd.
- 42.03
- 0.000.00%
Not Open Apr 2 09:30 CST
18.99BMarket Cap29.64P/E (TTM)
0.00High0.00Low0lotVolume0.00Open42.03Pre Close0.00Turnover0.00%Turnover Ratio29.64P/E (Static)451.88MShares48.2852wk High5.64P/B18.99BFloat Cap20.4252wk Low50.44Limit Up451.88MShs Float96.52Historical High33.62Limit Down0.00%Amplitude13.94Historical Low0.80Dividend TTM--Avg Price0lotAsk1.90%Div YieldTTM100Lot Size0lotBid
Autel Intelligent Technology Corp.,Ltd. Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 20.95%3.93B | 28.07%2.8B | 27.22%1.84B | 22.22%863.23M | 43.50%3.25B | 41.81%2.19B | 40.13%1.45B | 37.56%706.28M | 0.53%2.27B | -5.55%1.54B |
| Operating revenue | 20.95%3.93B | 28.07%2.8B | 27.22%1.84B | 22.22%863.23M | 43.50%3.25B | 41.81%2.19B | 40.13%1.45B | 37.56%706.28M | 0.53%2.27B | -5.55%1.54B |
| Total operating cost | 19.23%3.32B | 20.87%2.31B | 23.41%1.5B | 17.01%721.93M | 34.31%2.78B | 31.50%1.91B | 28.33%1.22B | 28.93%616.97M | 3.85%2.07B | 2.64%1.45B |
| Operating cost | 19.27%1.76B | 23.53%1.24B | 21.23%805.18M | 27.11%373.6M | 51.26%1.47B | 55.98%1B | 54.53%664.16M | 39.43%293.92M | 2.05%974.02M | -8.19%642.69M |
| Operating tax surcharges | 46.14%21.79M | 18.65%16.24M | 25.47%11.81M | 6.32%5.53M | -8.42%14.91M | 18.80%13.68M | 21.38%9.41M | 69.20%5.2M | 0.63%16.28M | -4.76%11.52M |
| Operating expense | 16.15%559.01M | 6.48%371.89M | 12.58%251.09M | 4.04%123.48M | 30.25%481.31M | 37.09%349.25M | 49.18%223.03M | 69.61%118.68M | 55.52%369.54M | 56.21%254.75M |
| Administration expense | 14.31%323.79M | 13.22%199.84M | 17.57%130.84M | 29.05%69.02M | 36.30%283.25M | -12.45%176.51M | -17.72%111.29M | -25.01%53.48M | -14.29%207.82M | 19.13%201.6M |
| Financial expense | 676.70%21.88M | 472.30%41.32M | 105.78%2.15M | -61.58%7.98M | 93.25%-3.79M | 79.57%-11.1M | -83.38%-37.09M | 129.81%20.77M | -190.00%-56.18M | -283.71%-54.31M |
| -Interest expense (Financial expense) | 3.54%69.5M | 8.90%53.37M | 11.41%35.97M | 13.27%18.24M | 59.88%67.13M | 121.71%49M | 336.96%32.28M | 592.43%16.1M | 237.72%41.99M | 116.08%22.1M |
| -Interest Income (Financial expense) | -148.47%-26.12M | -42.03%-14.64M | -41.88%-11.39M | -64.52%-6.4M | 40.97%-10.51M | 8.93%-10.31M | -35.21%-8.03M | 9.39%-3.89M | 20.01%-17.81M | 37.86%-11.32M |
| Research and development | 18.82%635.78M | 16.29%438.2M | 22.22%302.57M | 13.93%142.32M | -4.69%535.1M | -4.48%376.83M | 0.09%247.57M | 9.26%124.92M | 16.25%561.42M | 16.22%394.48M |
| Credit Impairment Loss | -32.21%-23.48M | -91.54%-23.39M | -160.08%-23.77M | -122.67%-4.39M | 9.22%-17.76M | 0.04%-12.21M | 6.86%-9.14M | 47.71%-1.97M | -68.47%-19.57M | -283.63%-12.22M |
| Asset Impairment Loss | -21.54%-93.16M | -222.47%-61.61M | -137.33%-30.72M | 85.85%-257.18K | -156.72%-76.65M | -306.04%-19.11M | -204.34%-12.94M | -222.11%-1.82M | -410.44%-29.86M | -58.78%-4.71M |
| Other net revenue | ||||||||||
| Fair value change income | 45.62%-8.08M | 43.80%-8.36M | -30.59%-8.43M | -152.69%-4.94M | -1,816.66%-14.85M | -43.71%-14.88M | 51.01%-6.46M | -173.75%-1.95M | 175.07%865.15K | -12.10%-10.36M |
| Invest income | 3,533.00%88.94M | 5,561.94%101.38M | 3,165.34%101.38M | 132.91%1.05M | 85.96%-2.59M | -128.93%-1.86M | -127.09%-3.31M | -124.15%-3.19M | -133.06%-18.45M | -83.97%6.42M |
| -Including: Investment income associates | ---11.09M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---199.42K | ---- |
| Asset deal income | -154.60%-277.12K | -687.50%-286.33K | -845.60%-259.97K | 109.92%21.34K | -49.06%507.5K | -94.62%48.74K | -103.03%-27.49K | -378.74%-215K | 205.71%996.29K | 214.00%906.73K |
| Other revenue | 10.73%71.59M | 26.72%59.56M | 25.72%36.39M | -14.41%15.03M | 3.17%64.65M | -3.80%47M | -3.10%28.94M | 8.34%17.56M | -38.72%62.67M | -32.01%48.85M |
| Operating profit | 54.22%648.36M | 101.32%565.59M | 82.30%412.7M | 51.25%147.81M | 122.08%420.41M | 129.81%280.94M | 127.80%226.38M | 50.90%97.72M | -52.36%189.3M | -61.58%122.25M |
| Add:Non operating Income | 174.32%3.17M | 99.35%541.01K | 8.40%258.04K | -63.21%80.94K | 306.80%1.16M | -3.44%271.39K | -1.78%238.03K | 14.32%220.01K | -80.15%284.19K | -43.85%281.05K |
| Less:Non operating expense | -94.36%14.37M | 28.43%1.5M | -17.52%851.71K | -11.34%238.22K | 21,840.56%254.62M | 0.89%1.17M | 5.39%1.03M | 293.47%268.7K | -92.52%1.16M | 1,120.41%1.16M |
| Total profit | 281.66%637.16M | 101.63%564.63M | 82.68%412.1M | 51.17%147.65M | -11.40%166.95M | 130.73%280.04M | 128.69%225.59M | 50.54%97.67M | -50.84%188.43M | -61.91%121.37M |
| Less:Income tax cost | 182.19%76.83M | 55.28%62.09M | 29.03%52.05M | -4.99%32.48M | -74.51%27.22M | 108.93%39.98M | 210.55%40.34M | 2,068.12%34.18M | 292.69%106.82M | 180.81%19.14M |
| Net profit | 301.04%560.34M | 109.35%502.54M | 94.36%360.06M | 81.40%115.17M | 71.21%139.72M | 134.82%240.05M | 116.28%185.25M | 0.29%63.49M | -81.40%81.61M | -70.13%102.23M |
| Net profit from continuing operation | 301.04%560.34M | 109.35%502.54M | 94.36%360.06M | 81.40%115.17M | 71.21%139.72M | 134.82%240.05M | 116.28%185.25M | 0.29%63.49M | -81.40%81.61M | -70.13%102.23M |
| Less:Minority Profit | -103.96%-80.59M | -46.31%-38.74M | -602.53%-26.51M | -12.97%-9.58M | -93.46%-39.51M | ---26.48M | ---3.77M | ---8.48M | ---20.42M | ---- |
| Net profit of parent company owners | 257.59%640.93M | 103.08%541.28M | 104.51%386.56M | 73.34%124.75M | 75.66%179.23M | 160.72%266.53M | 120.69%189.02M | 13.69%71.97M | -76.74%102.03M | -70.13%102.23M |
| Earning per share | ||||||||||
| Basic earning per share | 262.50%1.45 | 106.78%1.22 | 107.14%0.87 | 86.67%0.28 | 73.91%0.4 | 156.52%0.59 | 121.05%0.42 | 7.14%0.15 | -76.29%0.23 | -69.74%0.23 |
| Diluted earning per share | 255.00%1.42 | 114.55%1.18 | 115.38%0.84 | 86.67%0.28 | 73.91%0.4 | 139.13%0.55 | 105.26%0.39 | 7.14%0.15 | -76.04%0.23 | -69.33%0.23 |
| Other composite income | -84.93%-27.48M | -325.21%-20.34M | -261.22%-32.03M | -1,674.88%-16.49M | -150.63%-14.86M | -112.49%-4.78M | 4.08%19.87M | 58.88%-929.06K | 6,015.94%29.35M | 565.55%38.29M |
| Other composite income of parent company owners | -83.90%-27.27M | -328.88%-20.52M | -261.02%-31.99M | -1,674.07%-16.48M | -150.48%-14.83M | -112.49%-4.78M | 4.08%19.87M | 58.88%-929.06K | 6,021.23%29.38M | 565.55%38.29M |
| Other composite income of minority owners | -591.07%-208.8K | --175.66K | ---39.71K | ---7.5K | -15.14%-30.21K | ---- | ---- | ---- | ---26.24K | ---- |
| Total composite income | 326.76%532.86M | 104.96%482.2M | 59.92%328.03M | 57.74%98.68M | 12.53%124.86M | 67.43%235.27M | 95.83%205.12M | 2.48%62.56M | -74.68%110.96M | -59.63%140.52M |
| Total composite income of parent company owners | 273.26%613.65M | 98.96%520.77M | 69.74%354.57M | 52.40%108.27M | 25.11%164.4M | 86.27%261.75M | 99.44%208.89M | 16.37%71.04M | -70.01%131.41M | -59.63%140.52M |
| Total composite income of minority owners | -104.33%-80.8M | -45.65%-38.56M | -603.58%-26.55M | -13.06%-9.59M | -93.35%-39.54M | ---26.48M | ---3.77M | ---8.48M | ---20.45M | ---- |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | -- | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.